Blood Science Update | TREML2 Enhances Sensitivity of Acute Myeloid Leukemia Cells to Cytarabine via Suppression of the ERK Signaling Pathway

Blood Science Update | TREML2 Enhances Sensitivity of Acute Myeloid Leukemia Cells to Cytarabine via Suppression of the ERK Signaling Pathway

2025.08.14
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by clonal expansion of myeloid precursor cells. Cytarabine (Ara-C) remains a cornerstone of induction chemotherapy; however, primary and acquired resistance to Ara-C significantly limits its therapeutic efficacy. Emerging studies have suggested that immune checkpoint and receptor molecules may influence tumor chemosensitivity, yet the role of TREML2, a member of the TREM family, has remained largely unexplored in the AML context. This article, published in Blood Science, investigated TREML2 expression in AML and uncovered its role in modulating responsiveness to Ara-C.
Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial

Blood Science Update | Long-Term Outcomes of Cytarabine Use in Pediatric APL: 12-Year Follow-Up of a Randomized Controlled Trial

2025.08.14
Acute promyelocytic leukemia (APL) is among the most curable forms of pediatric acute myeloid leukemia, primarily due to the success of ATRA and arsenic trioxide (ATO)-based therapies. However, the contribution of cytarabine (Ara-C) to long-term outcomes remains debated. In this newly published study in Blood Science, researchers present the results of a prospective, randomized trial examining the long-term impact of adding Ara-C during consolidation therapy for children with APL.
Blood Science Update | Unexpected Poor Prognosis in ZNF618::NUTM1-Positive B-ALL: A Rare Case Defies Clinical Assumptions

Blood Science Update | Unexpected Poor Prognosis in ZNF618::NUTM1-Positive B-ALL: A Rare Case Defies Clinical Assumptions

2025.08.14
ZNF618::NUTM1-rearranged B-cell lymphoblastic leukemia (B-ALL) is recognized as a rare but favorable subtype of pediatric leukemia. However, this new case report published in Blood Science challenges that prognostic certainty, documenting a 3-year-old patient whose disease proved resistant to conventional chemotherapy, multiple CAR-T therapies, and hematopoietic stem cell transplantation. The findings underscore the need to reassess expectations surrounding NUTM1 fusion-positive leukemias and investigate the biological complexity behind treatment failure.
IDSC 2025丨Professor Yoshiaki Gu: From National Action to One Health Strategy – Japan’s Experience and Future Pathways in AMR Control

IDSC 2025丨Professor Yoshiaki Gu: From National Action to One Health Strategy – Japan’s Experience and Future Pathways in AMR Control

2025.08.08
ntimicrobial resistance (AMR) has become a major global public health challenge. To enhance capabilities in diagnosing and treating infectious diseases and promote rational use of antimicrobial agents in China, the 11th Academic Conference of the Infectious Diseases Society of China (IDSC) under the China Medicine Education Association was recently held in Beijing. At the conference, Professor Yoshiaki Gu from the Institute of Science Tokyo (Science Tokyo) shared Japan’s experience in AMR control. Infectious Disease Frontier invited Professor Gu to provide an in-depth analysis of the evolving threat of drug-resistant pathogens in Japan, the outcomes of its National Action Plan, and innovative public education initiatives. He further explored critical future directions for antimicrobial drug development and cross-sectoral collaboration under the "One Health" strategy.
Professor Dingwei Ye’s Team Showcases Surgical Expertise in Recurrent Prostate Cancer at the World Robotic Surgery Congress

Professor Dingwei Ye’s Team Showcases Surgical Expertise in Recurrent Prostate Cancer at the World Robotic Surgery Congress

2025.08.07
From July 15 to 18, 2025, the annual global summit in the field of robotic surgery—the World Congress of the Society of Robotic Surgery (SRS)—was held in France, drawing together leading surgeons and pioneers in robotic technology from around the world. The event featured discussions on cutting-edge innovations and future trends, along with the presentation of dozens of state-of-the-art surgical robot platforms and their development teams. Representing one of China’s foremost urologic oncology institutions, the Department of Urology at Fudan University Shanghai Cancer Center, led by Professor Dingwei Ye, actively participated in this global exchange, showcasing China’s expertise and innovation on the international stage.
Vitamin C Shows Promise in Treating Advanced Kidney Cancer: Breakthrough Mechanism Identified by Research Teams Led by Professors Liqun Zhou, Xuesong Li, and Weimin Ci

Vitamin C Shows Promise in Treating Advanced Kidney Cancer: Breakthrough Mechanism Identified by Research Teams Led by Professors Liqun Zhou, Xuesong Li, and Weimin Ci

2025.08.07
Vitamin C, a vital nutrient known for its antioxidant, immune-boosting, and cosmetic benefits, has long been a subject of interest in cancer research. While its anti-tumor properties have been explored for years, the scientific community has remained divided, and the precise mechanisms by which Vitamin C may act against cancer—particularly metastatic renal cell carcinoma (RCC)—have remained elusive.
2025 Beijing Breast Cancer Forum | Prof. Que Zhang: Enhancing Early Screening in Primary Care, Upholding the Mission of Breast Oncology Advancement

2025 Beijing Breast Cancer Forum | Prof. Que Zhang: Enhancing Early Screening in Primary Care, Upholding the Mission of Breast Oncology Advancement

2025.08.05
The 2025 Beijing Breast Cancer Forum and Breast Reconstruction Symposium, held from June 25 to June 28 in Beijing, was hosted by the Beijing Society for Breast Disease Prevention and Treatment and co-organized by the Breast Center of Peking University People’s Hospital and the Jiaqing Breast Cancer Prevention Foundation. During the conference, Oncology Frontier invited Prof. Que Zhang, Vice President of the Beijing Society for Breast Disease Prevention and Treatment, to provide in-depth insights into the current challenges and future directions of early breast cancer screening in primary care institutions in China. He also reflected on the broader significance of the newly launched “Peking University People’s Hospital Jiaqing Foundation Centennial Legacy Training Program.”
ASCO Focus | Prof. Songqing Ye: New Strategies, New Breakthroughs — Interpreting the TRADE and OASIS-4 Study Results

ASCO Focus | Prof. Songqing Ye: New Strategies, New Breakthroughs — Interpreting the TRADE and OASIS-4 Study Results

2025.08.05
At the 2025 ASCO Annual Meeting, two important studies—TRADE and OASIS-4—brought forward new treatment concepts and methods for early breast cancer, particularly in improving treatment adherence and patient quality of life. The TRADE study (Abstract No. 517) introduced a dose-escalation strategy for the CDK4/6 inhibitor abemaciclib in HR+/HER2− breast cancer patients, significantly improving adherence and tolerability. Meanwhile, the OASIS-4 study (Abstract No. 508) demonstrated, for the first time, the rapid onset and long-term safety of elinzanetant in alleviating vasomotor symptoms (VMS) caused by adjuvant endocrine therapy in HR+ breast cancer, offering a new option for enhancing quality of life and adherence. Oncology Frontier invited Prof. Songqing Ye of Fujian Provincial Hospital, affiliated with Fuzhou University, to provide in-depth insights into these two key studies.